This antibody is as efficacious as infliximab for the treatment of rheumatoid arthritis. IBD. Anti-interferon- and anti-CD25 therapies were developed, but the benefit of these agents has not yet been established. The selective blocking of migration of leukocytes into intestine seems to be a nice approach. Antibodies against 4 integrin and 47 integrin showed benefit for IBD. Antisense BST2 oligonucleotide of intercellular adhesion molecule 1 (ICAM-1) may be efficacious for IBD. Clinical trials of such compounds have been either recently reported or are currently underway. In this article, we review the efficacy and safety of such novel biological therapies for IBD. 4%). In a randomized, double-blind, placebo-controlled trial for the treatment of fistulizing disease, 94 CD patients with draining abdominal and perianal fistulas refractory to conventional therapy were treated with three intravenous infusions at wk 0, 2 and 6 of either a placebo or infliximab at a dose of 5 mg/kg or 10 mg/kg. The response rates were significantly greater in the infliximab 5 mg/kg group (68%) and in the infliximab 10 mg/kg group (56%) than that in the placebo-treated group (26%). The rates of a complete closure of the fistulas were also significantly higher in the infliximab 5 mg/kg group (55%) and in the infliximab 10 mg/kg group (38%) than in the placebo-treated group (13%). The effectiveness of infliximab for the maintenance therapy for inflammatory CD was assessed in a large trial Ivermectin called ACCENT I. Three hundred and thirty-five responders to a single infusion of infliximab were subsequently treated with 5 mg/kg infliximab at wk 2 and 6, followed by infusions of either 5 mg/kg or 10 mg/kg infliximab once every 8 wk until wk 54, or they were treated with placebo at wk 2 and 6, and subsequently every 8 wk. The rates of clinical response Ivermectin and remission at wk 30 and 54 was significantly greater in both groups receiving 5 mg/kg and 10 mg/kg infliximab every 8 wk than those in the placebo-treated group. In addition, an analysis comparing the scheduled and episodic treatment strategies of Ivermectin infliximab for CD was conducted based on the ACCENT I data. The efficacy of the scheduled therapy was better than episodic strategy in terms of CDAI score, clinical remission and response rates, improvement in IBDQ score, mucosal healing and CD-related hospitalization and surgery. For an evaluation of the infliximab maintenance therapy for fistulizing CD, ACCENT II trial was Ivermectin conducted. One hundred and ninety-six CD patients with draining perianal and enterocutaneous fistulas who responded to the induction therapy with three infusions of 5 mg/kg infliximab at wk 0, 2 and 6 received either a placebo or 5 mg/kg infliximab every 8 wk. The median time to the loss of response, response rate and complete fistula closure rate at wk 54 in the infliximab maintenance group were significantly greater than those in the placebo group. Regarding the safety of infliximab treatment, it is well tolerated in the majority of the patients. In randomized controlled clinical trials, the rates of adverse events occurring in infliximab-treated patients were comparable to those in placebo-treated patients[10-12,14]. Serious side effects, however, have been reported and attention must be paid to the possible occurrence of serious infections and autoimmune disorders, as well as the.